A Phase 2 interventional study of SPP635 in Hypertension and Type II Diabetes Mellitus, sponsored by Speedel Pharma Ltd.. Completed at 1 site in Ireland. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2008-11-21.
Sponsored by Speedel Pharma Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Hypertension with a site in Ireland — 5 open to participants now, 7 under way, 1 of them phase 3. Hypertension · Ireland.
Among the 28 studies in Hypertension with a site in Ireland, this one is the 26th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2007, is one of 5 in phase 2, and was the 6th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →5 of the 28 studies in Hypertension with a site in Ireland are open now. Recruiting first, the newest first:
Medtronic Vascular · Sites in Ireland, Australia, Belgium and 6 more countries
Ages 18+
Boehringer Ingelheim · Sites in Ireland, United States, Argentina and 48 more countries
Ages 18+
Medtronic Vascular · Sites in Ireland, Greece
Ages 20–70
Medtronic Vascular · Sites in Ireland, United States, Australia and 3 more countries
Ages 18–80
University College Dublin · Sites in Ireland
Ages 40+
A study can be open while its sites in Ireland have not opened yet or have stopped. Only those recruiting at a site in Ireland →
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 250 across the 27 interventional studies, 5,186 across the 1 observational. Of the 17 that completed or were terminated, 5 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
17 of 28 have an industry lead sponsor. The 10 most frequent:
Speedel Pharma Ltd. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Speedel Pharma Ltd. has 2 studies filed under Hypertension — fewer than ten, so there is no comparison to draw.
2 of the studies in Hypertension with a site in Ireland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07013929Medtronic VascularSpyral InSight Study | 2027-02-28 |
| NCT07115953Medtronic VascularStreamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension | 2027-10-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies in Hypertension with a site in Ireland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a phase II a, double-blind, randomized, parallel-design, four-week study to investigate the efficacy, safety and tolerability of two different doses of SPP635 in type II diabetic patients with mild to moderate hypertension and albuminuria.
The total study duration for patients completing the entire study will be approximately 7 weeks including a 2 weeks Screening Phase, 1 week Wash-out Phase, 4 week Treatment Phase and 1 week Follow-up Phase.
All treatments other than certain antihypertensive drugs (which are to be washed-out) with an effect on BP and all antidiabetic treatments must be kept at stable dose during the whole study.
A maximum of 50 patients in total is planned to be enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
high dose
Drug: SPP635
lower dose
Drug: SPP635
oral once daily
ABPM
Time frame: 28 days
sitting PB
Time frame: 28 days
The record gives a start of Nov 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Speedel Pharma Ltd.